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ABSTRACT
Peripheral nerve injuries (PNI) have a high prevalence and can be
debilitating, resulting in life-long loss or disturbance in end-organ function,
which compromises quality of life for patients. Current therapies use micro-
surgical approaches but there is the potential for enhancing recovery
through other therapeutic modalities such as; cell-based conduits, gene
therapy and small molecules. A number of molecular targets and drugs
which have the potential to improve nerve regeneration have been identi-
ﬁed, however, there are challenges associated with moving therapies toward
clinical translation. Due to the lack of detailed knowledge about the pro-
regenerative effect of potential drug treatments, there is a need for effective
in vitro models to screen compounds to inform future pre-clinical and clini-
cal studies. The interaction between regenerating neurites and supporting
Schwann cells is a key feature of the nerve environment, therefore, in vitro
models that mimic this cellular association are useful tools. In this study,
we have investigated various cell culture models, including simple mono-
layer systems and more complex 3D-engineered co-cultures, as models for
use in PNI drug development. Anat Rec, 301:1628–1637, 2018. © 2018 The
Authors. The Anatomical Record published by Wiley Periodicals, Inc. on
behalf of American Association of Anatomists.
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Damage to the peripheral nervous system can be
debilitating and result in loss of motor and sensory
function, coupled with poor neuron regeneration capac-
ity (Hoke and Brushart, 2010). Despite increased
understanding of the complex neuropathophysiology
following such an injury, the principal clinical treatments
have not changed in over 30 years (Faroni et al., 2015).
Microsurgery remains the gold standard therapy, but clini-
cal outcomes are often insufﬁcient and the patient is
unlikely to achieve complete recovery and regain function
(Hoke, 2006; Geuna et al., 2009). These surgical interven-
tions focus on bridging the injury site and do not address
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the complexity of cellular and molecular events occurring
along the entire length of the nerve (Faroni et al., 2015).
Consequently, other approaches to improve the clinical out-
come need to be considered.
At present, there are no drug treatments routinely
given following a PNI to improve regeneration, despite
increased understanding of the speciﬁc molecular and cel-
lular events that occur following injury. Appropriately
targeted therapeutic agents have the potential to main-
tain neuronal viability, encourage axonal growth over
larger inter-stump gaps, improve axonal speciﬁcity to
end-organ targets, and manage neuropathic pain (Hall,
2005; Faroni et al., 2015). Therefore, there is an unmet
clinical need for pharmacological therapies to improve
outcomes (Martinez de Albornoz et al., 2011).
The rate of attrition in drug discovery is high with 50% of
Phase III clinical trials failing and only 12% of compounds
tested in humans making it onto the market (Chuang-Stein
et al., 2004; Huang et al., 2011). Pre-clinical studies deter-
mining the efﬁcacy and safety of compounds are required by
regulatory bodies, for example the Medicines and Health-
care Products Regulatory Agency (MHRA) or the US Food
and Drug Administration (FDA) before any clinical trial
application (Steinmetz and Spack, 2009; Food and Drug
Administration [FDA], 2015). One reason drug therapies fail
to reach the market, is the lack of effective pre-clinical
models that mimic the pathophysiology and disease states
in humans to test potential compounds (Huang et al., 2011).
In addition, gaps in the understanding of cellular and molec-
ular mechanisms can make it challenging to correlate the
relationship between therapeutic targets and pathophysio-
logical conditions, making it difﬁcult to predict therapeutic
outcomes (Huang et al., 2011).
The pre-clinical stages of the drug discovery pipeline can
be divided into two parts (1) in vitro cell culture based stud-
ies and (2) animal studies. These are vital steps and provide
the raw data required to inform future clinical trials
(Steinmetz and Spack, 2009; FDA, 2015). In nerve repair as
in other ﬁelds, numerous models have been established to
test the efﬁcacy of compounds pre-clinically, and increasingly
a range of in vitro approaches are used prior to animal test-
ing. However, most tend to use monolayer cell cultures
which have limitations that may reduce their usefulness.
Despite advantages associated with their simplicity and
low cost, monolayer cell culture models often fail to represent
the complex 3D characteristics of living tissues (Hopkins
et al., 2015; Ko and Frampton, 2016). As cells are forced to
adhere to a ﬂat stiff plastic or glass surface during monolayer
culturing, they respond to spatial and mechanical cues that
are not present in their natural environment, which can sig-
niﬁcantly impact their behavior; function, growth, and mor-
phology (Ko and Frampton, 2016). The development of
effective 3D in vitromodels potentially enables researchers to
bridge between results obtained in monolayer in vitro models
and in vivo studies more successfully (Hopkins et al., 2015).
Consequently, as 3D cell cultures advance they could help
improve the pre-clinical development process and the success
of clinical trials (Ko and Frampton, 2016).
In addition, cell culture models commonly incorporate
enriched monocultures of single cell types and do not con-
sider the synergistic effect of the other cells present in nerve
tissue, resulting in an unrealistic representation of the phys-
iological environment (Ahmed et al., 2006; Kofron et al.,
2009; Kraus et al., 2015; Ko and Frampton, 2016). During
successful regeneration following nerve injury, Schwann
cells provide support to the neurons and, therefore, this 3D
cell-to-cell interaction is a key feature that should be recre-
ated to build more representative in vitro models (Chan
et al., 2014). Various 3D culture model systems have been
adopted by the biomaterials and tissue engineering commu-
nities to study the inﬂuence of extracellular matrices in
neurite formation and growth, but these tend not to have
been developed speciﬁcally for compound screening and
drug discovery (Baldwin et al., 1996; Herbert et al., 1998;
Pittier et al., 2005; Ahmed et al., 2006; Bozkurt et al., 2007;
Kofron et al., 2009; Kraus et al., 2015).
To maximize beneﬁt to PNI research, new in vitro models
need to build on and complement existing approaches while
overcoming particular limitations. Animal models of PNI
repair such as crush or transection and repair of a nerve in
rodents are widely used to test potential treatments (Angius
et al., 2012). However, while the complexity of such models
echoes that of the human clinical situation and provides
useful systems-level information, this complexity can be a
hindrance to understanding fundamental cellular processes
and mechanisms of action. Cell culture models on the other
hand permit a much greater degree of control and monitor-
ing, enabling speciﬁc variables to be isolated and detailed
cellular responses to be measured. Furthermore, cell cul-
tures are amenable to continuous monitoring whereas cell
and molecular information from animal experiments tends
to be available only as a snapshot at the end-point. The
potential for use of human cells in culture models may also
help to circumvent some of the concerns about differences
in responses to drug treatments between species. Finally,
the increased use of more sophisticated non-animal models
can help reduce, reﬁne, and replace the use of animals in
many experiments, in line with the requirements of the
3Rs in research (Russel and Burch, 1959).
One of the leading goals for drug therapies in PNI treat-
ment is to increase the rate of regeneration of neurites as
they extend through the injury site, and also through the
distal nerve segment, where they are supported and
guided by columns of Schwann cells that form the Bands of
Büngner. A culture model that recreates this 3D neuron-
glial interaction in a reliable and reproducible manner
would be a useful additional tool for testing potential drug
compounds that could modulate regeneration.
Engineered neural tissue (EngNT) refers to anisotropic
cellular hydrogels that have been developed for use in nerve
repair to deliver Schwann cells or Schwann cell-like thera-
peutic cells to mimic an autograft (Georgiou et al., 2013;
Martens et al., 2014; Georgiou et al., 2015; Sanen et al.,
2017; O’Rourke et al., 2018). This approach, however, also
has the potential to be used as a model for pre-clinical in vitro
drug screening as it enables quantiﬁcation of the regeneration
of neurons within an aligned 3D Schwann cell-seeded colla-
gen gel environment. When neurons are co-cultured with
EngNT, neurite growth is supported and guided by aligned
glial cells in a soft 3D extracellular matrix environment. This
neurite growth in vitro, therefore, mimics some of the key fea-
tures of the peripheral nerve environment distal to a PNI
repair. By standardizing a scalable co-culture methodology
and developing robust quantitation protocols, this approach
has the potential to be used as a model for drug screening.
The aim of this study was to compare monolayer and
3D EngNT co-culture nerve tissue models as potential
screening tools to enable progress toward the discovery of
drug therapies for PNI. Here, the models were compared
using ibuprofen as an exemplar potential drug for PNI, as
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it has previously demonstrated positive effects on nerve
regeneration (Fu et al., 2007; Madura et al., 2011). The
proposed approach will, however, be applicable to testing
a wide range of other candidate drug treatments.
METHODS
Cell Culture
SCL4.1/F7 Schwann cell line. Schwann cell line
SCL4.1/F7 (Health Protection Agency) cells were grown
in culture medium (DMEM; Sigma-Aldrich) supplemen-
ted with 10% heat inactivated fetal bovine serum (FBS)
(Biosera) and 100 U/mL of Penicillin, 100 μg/mL of Strep-
tomycin, in standard cell culture ﬂasks. The cultures
were maintained at sub-conﬂuency at 37C with 5% CO2
and passaged when required.
PC12 neuronal cell line. PC12 cells (rat neuronal
cell line, 88,022,401; Sigma-Aldrich) were grown in sus-
pension in culture medium (RPMI 1640; Sigma-Aldrich)
supplemented with 100 U/mL of Penicillin, 100 μg/mL of
Streptomycin, (Sigma-Aldrich), 2 mM L-glutamine, 10%
vol/vol heat-inactivated horse serum, and 5% vol/vol fetal
calf serum (Sigma-Aldrich) in standard cell culture ﬂasks.
The cultures were maintained at sub-conﬂuency at 37C
with 5% CO2 and passaged when required.
NG108–15 neuronal cell line. NG108–15 cells (rat
neuronal cell line, Sigma-Aldrich) were grown in culture
medium (DMEM, Sigma-Aldrich) in standard cell culture
ﬂasks. The cultures were maintained at sub-conﬂuency at
37C with 5% CO2 and passaged when required.
Dorsal root ganglion harvest and culture. Dorsal
root ganglion (DRG) neurons were obtained from adult
Sprague Dawley rats. The spinal column was excised from
rats that were culled using a Schedule 1 method (CO2
asphyxiation) according to local regulations. Using an
Olympus SZ40 dissecting microscope the DRGs were
removed and incubated with 0.125% collagenase type IV
(Sigma-Aldrich) at 37C for 90 min, then dissociated by
trituration. Collagenase was removed by two consecutive
20 mL washes using culture medium (DMEM; Sigma-
Aldrich) supplemented with 10% heat inactivated fetal
bovine serum (FBS) (Biosera) and 100 U/mL of Penicillin,
100 μg/mL of Streptomycin.
Crude DRG cell suspension was incubated in DMEM
culture medium supplemented with 0.01 mM cytosine
arabinoside (Sigma-Aldrich) in a poly-D-lysine (Sigma-
Aldrich) coated ﬂask at 37C, 5% CO2 for 24 hr. Cells
were detached using 0.25% (wt/vol) trypsin–EDTA solu-
tion and centrifuged at 400g for 5 min. The supernatant
was discarded and the DRGs were re-suspended in
DMEM culture medium for use in experimental studies.
Monolayer Cell Cultures
Neuronal cells (PC12, NG108-15, and DRGs) were
seeded at a density of 10,000 cells for cell lines, or cells
Fig. 1. Ibuprofen induces neurite growth in monolayer NG108–15 neurons. Signiﬁcant increases in neurite length were seen in the presence of
100 μM and 200 μM ibuprofen when compared to the no-drug treatment control, after 72 hr exposure. No neurite growth was seen with the growth
inhibitor GW9662 (a). Fluorescence micrographs of the monolayer cultures show neurite length with (b) no drug treatment, (c) 100 μM GW9662, (d)
10 μM ibuprofen, (e) 100 μM ibuprofen and (f) 200 μM ibuprofen. Cultures were immunostained to detect β-III tubulin (green). N = 6, mean  SEM
for each condition. One-way ANOVA with Tukey’s post hoc test, ***P < 0.001 and ****P < 0.0001.
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from one DRG per coverslip, onto poly--lysine (Sigma-Aldrich,
St. Louis, MO) coated coverslips (13 mm) for analysis.
Fabrication of 3D EngNT Co-cultures
Anisotropic cellular gels were prepared as described pre-
viously (Phillips and Brown, 2011). Brieﬂy, 1 mL of a solu-
tion containing; 80% (vol/vol) Type I rat tail collagen
(2 mg/mL in 0.6% acetic acid, First Link), 10% (vol/vol)
minimum essential medium (Sigma-Aldrich), 5.8% (vol/vol)
neutralizing solution (TAP Biosystems), and 4.2% Schwann
cell suspension (4 × 106 SCL4.1/F7 cells per 1 mL gel) was
integrated with tethering mesh at opposite ends of a rect-
angular mold (Dimensions 16.4 mm × 6.5 mm × 5 mm)
(East et al., 2010). Cellular gels were immersed in 10 mL
DMEM medium and incubated at 37C with 5% CO2 for
24 hr to enable cellular self-alignment, then stabilized
using plastic compression (120 g weight for 1 min). Each
stabilized aligned cellular gel was cut into four equal seg-
ments to obtain a control within each set of gels. Each gel
segment was transferred to a separate well in a 24-well
plate, then 100,000 PC12 or NG108–15 cells, or DRGs in
50 μL medium were seeded on top of each segment for co-
cultures. The gels were incubated for 1 hr at 37C to allow
attachment of neuronal cells to the collagen gel, then 1 mL
of culture medium (DMEM; Sigma-Aldrich), supplemented
with 10% (vol/vol) heat inactivated fetal bovine serum
(FBS) (Biosera), 100 U/mL of Penicillin and 100 μg/mL of
Streptomycin, was added to each well. The neurons were
seeded onto the top surface of the gels and neurites
extended across the horizontal plane following the aligned
Schwann gels (Fig. 3C).
Drug Treatments
Monolayer cell cultures or 3D EngNT co-cultures were
subjected to treatments of ibuprofen or GW9662
(Generon), a potent PPAR-γ antagonist (Lezana et al.,
2016), for 72 hr before being ﬁxed with 4% paraformalde-
hyde (PFA) for relevant analysis. A concentrated stock
solution of ibuprofen and GW9662 (10 mM) was added
directly to the media in the appropriate volume to provide
the required drug concentration.
Surgical primary repair in vivo
All surgical procedures were performed according to
the UK Animal Scientiﬁc Procedures Act 1986 after
approval by the UCL Animal Welfare and Ethics Review
Board. Adult male Wister rats (220–250 g) were deeply
anesthetized by inhalation of isoﬂurane, and the left sci-
atic nerve was exposed at mid-thigh level. The nerve was
completely transected and the two stumps re-connected
using two 10/0 epineurial sutures (Ethicon). An osmotic
pump (Alzet Model 1004) pre-loaded with vehicle control
or drug treatment (saline or ibuprofen (7 μg/day) equiva-
lent to the in vitro dose) was implanted locally parallel to
the nerve. The overlying muscle layers and skin were
closed, and the animals were allowed to recover and
maintained for 21 days.
Fig. 2. Ibuprofen induces neurite growth on monolayer crude prep DRG neurons. Signiﬁcant increases in neurite length were seen with 10 μM
and 100 μM doses of ibuprofen, however, all doses increased neurite growth when compared to no drug control (shown by dotted line) and 100 μM
GW9662 (shown in red) after 72 hr exposure (a). Fluorescence micrographs of the cultures show neurite length with no drug treatment (b), and
100 μM ibuprofen (c). Cultures were immunostained to detect β-III tubulin (green). N = 6, mean  SEM for each condition One-way ANOVA with
Dunnett’s post hoc test, **P < 0.01.
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Animals were then culled using CO2 asphyxiation,
according to local regulations. The repaired nerves were
excised under an operating microscope and immersion-
ﬁxed in 4% PFA. Following incubation in 30% (wt/vol)
sucrose and subsequent snap freezing in FSC 22 Frozen
Section Media (Leica), transverse sections (10-μm thick)
were prepared from the distal stumps, at a distance
5 mm into the nerve stump from the injury site.
Immunocytochemistry
Following ﬁxation with 4% PFA monolayer cells or
gels were washed three times with phosphate buffered
saline (PBS) and permeabilized using 0.5% Triton-X-100
(Sigma-Aldrich) in PBS. Washes were repeated before
blocking using horse serum (1:20 in PBS; Vector Labora-
tories). Gels were washed before the addition of primary
antibody of interest, (mouse anti-βIII-Tubulin 1:400
(Sigma-Aldrich); diluted in PBS). The antibody and gel/
cells were incubated overnight at 4C. Washes were
repeated before adding the corresponding secondary
antibody (Dylight anti-mouse IgG 488 1:400, (Vector
Laboratories) diluted in PBS). The antibody was
washed, and the sample was stored at 4C before view-
ing. Omission of primary or secondary antibody was rou-
tinely used as a control.
Fig. 3. Ibuprofen increases neurite growth in the 3D EngNT co-culture model with both cell lines; (a) PC12 and (b) NG108–15. A signiﬁcant
increase in growth was seen with 100 μM ibuprofen but not with 10 μM with both cell lines. Additionally, no signiﬁcant increase in neurite growth
was seen with a 200 μM dose. Representation of 3D EngNT containing aligned Schwann cells (green) and neurons seeding on the gel surface (red)
(c). Fluorescence micrographs of PC12 neuronal cells seeded on the gels without (d) and with (e) 100 μM drug treatment. Cultures were
immunostained to detect β-III tubulin (green). N = 6 of PC12 co-culture and N = 3 of NG108–15 co-culture gels, mean  SEM for each condition.
One-way ANOVA with Dunnett’s post hoc test, *P < 0.05, **P < 0.01, and ****P < 0.0001.
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Immunohistochemistry
Nerve sections were washed in immunostaining
buffer (PBS together with 0.2% Triton-X (Sigma-
Aldrich), 0.002% sodium azide (Sigma-Aldrich) and
0.25% Bovine Serum Albumin) before the addition of
horse serum (1:20 in immunostaining buffer) for
45 min. The blocking serum was then removed and sec-
tions were incubated in anti-neuroﬁlament antisera
(1:1000 in immunostaining buffer) (Neurogentec) over-
night at 4C. The sections were then washed with
immunostaining buffer before addition of the second-
ary antibody, Dylight anti-mouse IgG 549 (1:200)
(Vector Laboratories) and incubation at room tempera-
ture for 45 min. Sections underwent a ﬁnal wash with
immunostaining buffer before mounting with Vecta-
shield (Vector Laboratories).
Image Analysis and Quantiﬁcation
Fluorescence microscopy (Zeiss Axiolab A1, Axiocam
Cm1) was used to capture images of neurites from ﬁve
pre-determined ﬁelds of each gel or coverslip using a ×20
lens. The neurite number in the determined ﬁelds
depended on the cell type and model used (~1–12 neurites).
Brieﬂy, the positions of the pre-determined ﬁelds on cover-
slips were equally spaced (625-μm apart) in a line across
the diameter at the center of the coverslip, for the gels the
same method was used but the line of ﬁelds was along the
edge of the construct where alignment was greatest. The
length of each neurite in each ﬁeld was measured using
ImageJ. Following stabilization the gel acquired a thick-
ness of 100 μm and the neurons extended predominantly
in a single horizontal plane along the top surface, following
the aligned Schwann cells (Phillips, 2014). This allowed
analysis of neurite growth to be comparable between both
the monolayer and 3D co-cultures.
Tile scans were used to capture high-magniﬁcation
(x20) micrographs from the entire nerve cross-section
using a Zeiss LSM 710 Confocal microscope and images
were analyzed using Volocity™ 6.4 (PerkinElmer) run-
ning automated image analysis protocols to determine
the number of neuroﬁlament-immunoreactive neurites in
each transverse nerve section.
Fig. 4. Ibuprofen induces neurite growth in the 3D EngNT co-culture model with DRGs (a). A signiﬁcant increase was seen with a dose of 100 μM
ibuprofen but not 10 μM. Fluorescence micrographs of DRG neurons on EngNT gels without (b) and with (c) 10 μM drug treatment and (d) 100 μM
drug treatment. Cultures were immunostained to detect β-III tubulin (green). N = 6, mean  SEM for each condition. One-way ANOVA with
Dunnett’s post hoc test, *P < 0.05.
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Statistical Analysis
Normality tests were conducted on all data to determine
appropriate statistical tests, and one-way analysis of vari-
ance (ANOVA) or t-tests were performed, as data followed a
normal distribution. A one-way ANOVA was followed by a
Tukey or Dunnett post hoc test. For all tests, *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001 were consid-
ered to be signiﬁcant. Data are expressed as means  SEM
when described in the text.
RESULTS
Effect of Ibuprofen on Monolayer Cell Cultures
PC12 and NG108–15 cell lines. To investigate
the effect of ibuprofen on isolated PC12 and NG108–15
neurons, the two cell lines were seeded onto coverslips.
The cells were incubated for 72 hr with various concentra-
tions (10, 100, and 200 μM) of ibuprofen or 100 μM of the
PPAR-γ antagonist GW9662, (Lezana et al., 2016). No
neurite growth was seen with the PC12 cell line (data not
shown). However, signiﬁcant neurite growth was
observed following treatment of NG108-15 neurons with
10 μM (110  10 μm) and 100 μM (202  16 μm) ibuprofen
in comparison with the no-drug control (79  7 μm) and
GW9662 (Fig. 1). A higher dose of 200 μM elicited a simi-
lar effect on neurite growth to the lower dose of 100 μM.
Dorsal root ganglion cultures. Crude prepara-
tions of dissociated DRGs were used to determine the
pro-regenerative effects of ibuprofen on primary neurons.
The monolayer neural cell cultures were coated on glass
coverslips and subjected to ibuprofen treatments ranging
from 0.1 to 100 μM, or 100 μM GW9662, for 72 hr. Ibupro-
fen treatment led to an increase in neurite length in a
dose-dependent manner with a signiﬁcant increase seen
with 10 μM (467  25 μm) and 100 μM (488  58 μm) in
comparison to the no-drug control or GW9662 treat-
ment (Fig. 2).
Effect of Ibuprofen in 3D EngNT Co-cultures
PC12 and NG108–15 cell lines. Three-dimensional
EngNT co-culture models were used to investigate the
capacity of ibuprofen to modulate neurite outgrowth in
two neuronal cell lines; PC12 and NG108–15. Ibuprofen
was found to induce neurite extension in both cell lines in
a similar dose-dependent manner at concentrations of
10 μM (PC12: 101  10 μm, NG108: 85  2 μm) and
100 μM (PC12: 112  13 μm, NG108: 116  10 μm) ibu-
profen, however, minimal increase in neurite length was
seen with a dose of 200 μM ibuprofen (Fig. 3). An increase
in comparison to the control and antagonist GW9662 was
observed at concentrations of 10 and 100 μM.
Dorsal root ganglion neurons. Three-dimensional
EngNT co-culture models were fabricated using DRG pri-
mary neuronal cells to determine the effect of ibuprofen
on neurite outgrowth. When treating the DRGs with ibu-
profen, a dose response similar to that with PC12 and
NG108–15 cell lines was observed. At concentrations of
10 μM (198  14 μm) and 100 μM (249  26 μm), a signiﬁ-
cant increase in neurite length in comparison to the con-
trol (140  3 μm) was seen (Fig. 4), however, the mean
neurite growth was longer with DRGs.
Regenerative capacity of ibuprofen in
vivo. Transverse sciatic nerve sections were analyzed
for axon number. Results demonstrated that a dose of
7 μg/day ibuprofen increased the number of axons in the
distal stump in comparison to no drug treatment
(Fig. 5). Furthermore, the number of axons quantiﬁed in
the distal stump of the ibuprofen group exceeded the
axon number in the corresponding proximal stump of
the same animal (data not shown).
Fig. 5. Ibuprofen increases the number of neurites detected in the
distal stump 5 mm from the injury site following a local dose of 7 μg/
day ibuprofen for 21 days. N = 3 animals per group. Mean  SEM for
each condition. T-test, **P < 0.01.
Fig. 6. The data sets for the 100 μM dose of ibuprofen in the various
different in vitro models were normalized to their respective controls
and presented as fold changes over the no drug treatment condition.
Neurite growth increase was seen in all of the in vitro models except the
monolayer PC12 cultures where no growth was seen. N = 6 (N = 3 for
NG108–15 3D co-culture). Mean  SD.
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DISCUSSION
There is a growing interest in the development of
in vitro models that can accurately simulate the natural
regeneration process of neurons following a PNI. Monolayer
in vitro systems have been developed by co-culturing neu-
rons with Schwann cells to study the inﬂuence of cell-to-cell
interactions (Clarke et al., 2011), however, more complex 3D
co-culture systems have been developed to mimic the natu-
ral nerve environment more closely such as; explant cul-
tures (Yip et al., 1998; Miller et al., 2001; Vikman et al.,
2001; Lesuisse and Martin, 2002) self-assembled aggregate
cultures (Knoops et al., 1991; Becq et al., 1999; Jerregard,
2001; Lillesaar et al., 2001; Ruscheweyh and Sandkuhler,
2001; Edoff and Jerregard, 2002; Lee et al., 2002), and scaf-
fold based cell cultures (Borkenhagen et al., 1998; Dubey
et al., 1999; Backstrom et al., 2000; Balgude et al., 2001; Yu
and Bellamkonda, 2001; Georgiou et al., 2013).
Regardless there is still an unmet requirement for a
model to screen the effect of drug therapies on neuron regen-
eration. This study investigated the effectiveness of different
culture systems in terms of suitability for use in PNI drug
development, by investigating the effect of ibuprofen on the
length of neurites in the culture systems in comparison with
an in vivo study. Overall, ibuprofen increased neurite length
in the models regardless of the type of neurons and the com-
plexity of the culture environment. This was consistent with
the in vivo study, and also mimicked effects reported follow-
ing treatment with ibuprofen in previous studies.
These studies have shown neurite growth enhancement
in primary neuronal cell cultures following ibuprofen
treatment in a dose-dependent manner (Fu et al., 2007;
Wang et al., 2009; Dill et al., 2010). The effect of ibupro-
fen on neurite growth has also been demonstrated in rat
models of both the central and peripheral nervous sys-
tem, with axonal sprouting induced by ibuprofen treat-
ment following a contusion injury (Wang et al., 2009), the
promotion of axonal growth following spinal cord lesions
(Fu et al., 2007), and improved axonal areas and myelin
in peripheral nerve repair (Madura et al., 2011). Adding
to these earlier ﬁndings, this is the ﬁrst report showing a
signiﬁcant increase in neurite number in the distal stump
induced by ibuprofen treatment following a primary
repair in a rat sciatic nerve.
Similar patterns of dose–response were achieved fol-
lowing ibuprofen treatment when using either the PC12
or NG108–15 neuronal cell lines or primary neurons in
the 3D EngNT co-culture model. With all cell types, the
optimal dose was 100 μM ibuprofen which increased
growth by ~60%–70%. In contrast, in the monolayer cul-
tures no growth was seen with the PC12 neuronal cell
line, indicating that the 3D EngNT co-culture environ-
ment is required in order for that cell line to extend neur-
ites in these studies.
Nonetheless, the results observed from the monolayer
NG108–15 and DRG cultures still demonstrated extensive
neurite elongation following ibuprofen treatment. Interest-
ingly, the extent of growth in these cultures was different to
that seen in the 3D system. Even though the optimal dose
remains as 100 μM ibuprofen, the growth increase in
response to the drug exceeds 100%, considerably higher
than that seen in the 3D system. Also the 200 μM dose in
the NG108–15 monolayer culture elicited an increase in
neurite length in comparison to the control which was not
observed in the 3D-engineered co-culture.
To progress toward the development of a model to be
used as a screening tool for PNI therapies, a metric was
devised to compare the different in vitro models and to
determine which one best predicted the effect seen
in vivo. The in vivo model demonstrated a twofold
increase in neurite number following 7 μg/day of ibupro-
fen administered locally for 21 days. The dose adminis-
tered in vivo was approximately equivalent to the 100 μM
dose the cells were subjected to in vitro. Therefore, the
data sets for this dose were analyzed from each culture
model, by normalizing them to their controls. This analysis
showed that the monolayer models had marked variability
in neurite length. Although the DRG and NG108–15 mono-
layer cultures had comparable fold increases, they had a
large standard deviation (e.g., 60% in the NG108–15 cul-
ture) (Fig. 6). Conversely, the 3D models were more consis-
tent, with a standard deviation of 40% independent of
the cell type used. Furthermore, the 3D EngNT co-culture
with DRG neurons demonstrated a fold increase in neurite
length that is most comparable to the in vivo model.
Cell choice is an important consideration for in vitro
experiments and there is invariably a trade-off between
the ready availability, standardization, and reproducibil-
ity of immortalized cell lines (e.g., NG108–15, PC12,
SCL4.1/F7) and the use of primary cells which behave
more naturally but have additional limitations in terms
of source and variability. Species differences may also be
a consideration depending on the purpose of the experi-
ment (as a precursor to animal studies then animal cells
may be more appropriate, but in turn they may be less
appropriate for modeling human physiology). Comparable
effects were seen between cell lines and primary neurons
following ibuprofen treatment in this study, indicating
that the cell lines provided a valid prediction of the effects
of drugs without the need for primary cells in this
instance. Further development to ensure the model is
reproducible in other laboratories, with deﬁned intra and
inter observer reliability and intra class correlation, will
be required to facilitate scalable manufacture and subse-
quent widespread adoption.
CONCLUSION
The synergistic activity of neurons and Schwann cells
plays a key role in nerve regeneration; therefore, it is
desirable to recreate this key cell-to-cell interaction in a
model when evaluating the effects of drug therapies.
Using a tool that is more biologically comparable than a
monolayer culture of isolated cells may provide pertinent
data on drug safety and efﬁcacy to inform subsequent ani-
mal and clinical studies. This 3D EngNT co-culture model
system allows the exploration of key regenerative events
such as neurite formation and optimal dosing regimens
and could also be used to understand the mechanism of
action of drug candidates.
Using 3D co-culture systems increases complexity and
can introduce time restraints and restrictions to the num-
ber of samples (Ko and Frampton, 2016), however, our
analysis indicates that the 3D EngNT co-culture systems
are predictive of ibuprofen response in vivo, and also
more predictable in terms of outcome measures than their
monolayer counterparts.
In conclusion, we have taken a step closer to generat-
ing a model that represents the complex environment of
PNI, providing for the ﬁrst time a 3D co-culture model of
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PNI developed speciﬁcally for drug discovery and develop-
ment. The model enables medium throughput drug
screening with results that are predictive of the neuro-
therapeutic outcome.
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